Jia-Lu Shan,Kai-Ming Zhang,Wen-Qing Zhong et al. Jia-Lu Shan et al.

Although the development of targeted therapies as well as immune checkpoint inhibitors has led to a substantial improvement in the overall survival of patients with NRAS wild-type tumors, current therapies for NRAS-mutant cancers are limited.

Chengli Yang,Xukun Liao,Yilin Wang et al. Chengli Yang et al.

Osteoarthritis (OA) affects more than 250 million people worldwide, with current therapies focused primarily on symptom management rather than addressing underlying disease mechanisms.

Anam Ashfaque,Yara Shatnawi,Shahzad Raza et al. Anam Ashfaque et al.

Overall, CAEL-101 has demonstrated a favorable toxicity profile and improved organ responses, with faster treatment response time than current therapies in phase I/II trials, and is expected to have promising outcomes in the ongoing phase III studies.

Guanghui Wu,Yisheng Chen,Chong Chen et al. Guanghui Wu et al.

Although current therapies such as chemotherapy, radiotherapy, and targeted treatments have extended patient survival to some extent, their efficacy remains limited and is often accompanied by severe side effects.

Mohamed J Saadh,Omer Qutaiba B Allela,Ali Fawzi Al-Hussainy et al. Mohamed J Saadh et al.

Autoimmune diseases (AIDs) are marked by systemic inflammation and immune dysregulation, yet current therapies often fail to target their underlying causes.

Muhammad Bilal Azmi,Han Yu,Arisha Sohail et al. Muhammad Bilal Azmi et al.

However, current therapies have many side effects and limitations. Propolis, a resinous product of bee hives, possesses a variety of biological activities, including anticancer and chemo-protective properties.

Jinling Bi,Yong Huang,Wentao Hu et al. Jinling Bi et al.

Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally, yet current therapies exhibit suboptimal efficacy with limited prognostic improvement.

Christina Li-Ping Thio,Jheng-Syuan Shao,Chia-Hui Luo et al. Christina Li-Ping Thio et al.

Finally, we explore current therapies targeting these cells and their effector cytokines for asthma management.

Marelisa Albelo-Martínez,Syed Rizvi Marelisa Albelo-Martínez

Progressive forms of multiple sclerosis (MS) include primary progressive MS (PPMS) and secondary progressive MS (SPMS). Unlike relapsing-remitting MS (RRMS), progressive MS is recognized by relentless progression with accumulating disabilit...

Roya Ghafoury,Mojtaba Malek,Faramarz Ismail-Beigi et al. Roya Ghafoury et al.

We evaluate the anti-inflammatory mechanisms of current therapies such as statins, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide 1 (GLP-1) receptor agonists, as well as emerging agents like colchicine and interleukin (IL)-1β/IL-6 inhibitors, emphasizing their differential